Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Allergy & Immunology
•
Asthma
Should in-office oscillometry for lung function measurements be utilized in pediatric patients who are unable to reliably perform spirometry?
Related Questions
What factors do you consider prior to offering a trial of ICS/LABA therapy versus a methacholine challenge test in patients with suspected asthma but normal pulmonary function testing?
How do you decide when to add a second biologic agent to a patient’s asthma treatment who has either not responded or had a partial response to dupilumab, omalizumab, mepolizumab, or tezepelumab?
What is your preferred biologic for an asthmatic patient with a T2 low phenotype and who is a smoker?
Which patient characteristics or scenarios drive you to choose tezepelumab over dupilumab for asthma?
When would you recommend prescribing an asthmatic patient budesonide/salbutamol rather than budesonide/formoterol?
Is there a role for biologics to improve lung function in patients who have severe asthma with daily symptoms and reduced lung function but do not experience frequent exacerbations?
Do you feel high dose Symbicort or Dulera is appropriate to use for SMART despite these doses not being studied in clinical trials?
Do you utilize urinary leukotrienes as a marker for initiation of montelukast?
Is methacholine challenge on its way out?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
